lunes, 27 de diciembre de 2010

Perioperative Care of a Patient with Acute Fatty Liver
of Pregnancy
Robert S. Holzman, MD*†, Laura E. Riley, MD††, Eugene Aron, MD§, and
Janet Fetherston, CRNA*
*Department of Anesthesia, Newton Wellesley Hospital, Newton, MA; †Department of Anesthesia, Children’s Hospital,
Boston, MA; ††OB/GYN Infectious Disease, Maternal Fetal Medicine Services, Massachusetts General Hospital, Boston,
MA; and §Department of Obstetrics and Gynecology, Newton Wellesley Hospital, Newton, MA

Report of Case
A previously healthy 63 kg, 31-yr-old G1P0 female at 34 weeks’ gestation complained of fatigue, nausea, and vomiting 8 days before admission. She was treated as an outpatient 5 days before admission for flu-like symptoms and dehydration with IV fluids and 2 days before admission with IV fluids, sodium citrate, ondansetron, and prochlorperazine until the nausea subsided and she returned home. Her physical examination was unremarkable and no diagnostic studies were performed. On the day of admission she had scleral icterus. Her heart rate was 115 bpm, her blood
pressure was 122/67 mm Hg and her oxygen saturation by pulse oximetry (Spo2) was 92% on a 40% Venti mask. She was somnolent but aroused easily, was oriented to person, place, and time, and had no focal neurological findings. The airway evaluation revealed full range of motion of the head and neck with a Class 1 airway. Her gag reflex was diminished and her deep tendon reflexes were brisk bilaterally with 2–3 beats of clonus; mild asterixis and pedal edema were noted. An abdominal sonographic examination demonstrated neither gallstones nor dilation of the biliary ducts.
Her hepatitis B surface antigen was negative; other viral antigen levels were not obtained. Her hematocrit and platelet counts were 39.8% and 175,000/mm3 respectively. Them prothrombin time (PT) was 18.5 s, the partial thromboplastin
time was 42.7 s with an international normalized ratio of 2.2 and a fibrinogen level of 62 mg/dL. The thrombin time was 26.7 s and partially corrected to 17.2 s; the d-dimer level was .1 mg/mL. Her blood urea nitrogen and creatinine were 26 and 3.2 mg/dL, respectively. The serum glucose was 84 mg/dL and the ammonia 25 mmol/L. The aspartate aminotransferase was 223 U/L, the lactate dehydrogenase 1,038 U/L, the alanine aminotransferase 314 U/L, the g-glutamyl transferase 88 U/L, and the alkaline phosphatase 422 U/L. The cholesterol level was 52 mg/dL. The total bilirubin level was 9.7 mg/dL, the majority of which was direct. The fetal
heart rate was 130–140 bpm with acceleration to 156 bpm. A clinical diagnosis of severe preeclampsia with hemolysis, increased liver enzymes and decreased platelets(HELLP) syndrome and/or AFLP was made; expeditious operative delivery was the obstetrical treatment plan because of the patient’s increasing somnolence since her initial evaluation.

Discussion

The incidence of AFLP is estimated at 0.6 –1.5 per 10,000 deliveries (1–3), much less than the incidence of HELLP syndrome, which occurs in 10–60 of 10,000 deliveries. Preeclampsia occurs in approximately 50% of AFLP cases. Half the AFLP cases occur in primigravidae and 10–15% occur in twin pregnancies.
Though once thought not to recur in subsequent pregnancies (4,5), at least six cases of recurrent AFLP have been reported since 1990 (3,6 –9). The mortality of AFLP was 92% before 1970; currently it is ,10% because of early diagnosis of less severe forms and aggressive treatment of more severe forms.
The biochemical lesion may be either an isolated deficiency of long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or a complete deficiency of a trifunctional protein that catalyzes the last three steps of mitochondrial fatty acid oxidation. Deficiency of LCHAD has been found in children of women who
had AFLP or HELLP syndrome during pregnancy. Severe preeclampsia appears to increase the risk of AFLP in such women (10). Because the initial symptoms of AFLP are nonspecific, a high index of suspicion is necessary. AFLP is more likely to result in marked hypoglycemia, hyperammonemia, and an increased clotting time than is HELLP, although the liver enzyme abnormalities are usually more pronounced in HELLP syndrome than in AFLP; overlapping findings among the microangiopathies of pregnancy make the diagnosis challenging. In our patient, the coagulopathy and hypofibrinogenemia required aggressive support with blood component therapy. Our initial therapeutic goal was a fibrinogen level of 100 mg/dL and eventual correction of the PT and international normalized ratio by administering cryoprecipitate and FFP. Although it was unclear if the coagulopathy was strictly a primary
fibrinolysis as a result of the hepatic failure or whether an additional secondary fibrinolysis was present, the coagulopathy was ultimately resolved through aggressive supportive therapy as well as gradual hepatic recovery.
Mg21 treatment was initiated because the patient had brisk deep tendon reflexes and an alteration in mental status. Although it is surprising that respiratory insufficiency occurred with a [Mg21] of 8.2 mg/dL, the discontinuation of the Mg21 infusion and decrease in [Mg21] to 4.8 mg/dL was the only intervention before extubation. As Mg21 is excreted by the kidneys, it must be given with frequent clinical and biochemical monitoring and in reduced doses in the presence of impaired renal function.
Nevertheless, perhaps the combined hepatic and renal dysfunction rendered this patient with AFLP more
symptomatic at a lower threshold of hypermagnesemia. Anesthetic care of the patient with severe hepatic dysfunction includes meticulous attention to procedures performed during their coagulopathic state.
Gentle laryngoscopy with direct visualization of the airway during profound neuromuscular blockade is key in minimizing airway trauma and bleeding. In the midst of aggressive support with blood products, it
may be difficult to judge functional hepatic recovery using PT and partial thromboplastin time. Hyperbilirubinemia is neither a sensitive indicator of the severity of hepatic disease nor a negator of hepatic improvement, because confounding factors existed perioperatively for the increase of both the direct and indirect fractions. Moreover, changes in plasma albumin levels reflect neither acute liver dysfunction nor recovery. Although the liver is the sole source of albumin
synthesis, the plasma half-life of albumin is approximately 15 days with a 5%–8% breakdown rate per day. Acute parenchymal liver disease is commonly associated with increased plasma triglycerides,
decreased cholesterol esters, and abnormal lipoproteins, which may be very sensitive markers for hepatic injury and recovery. In pregnancy, this disparity may become more apparent because the serum level of free
and esterified cholesterol is larger than in nonpregnancy. Although the transfusion of FFP (usual free cholesterol 30–100 mg/dL) will increase the plasma cholesterol, our transfusion of 8 U of FFP within the first 24 hours would likely have increased the cholesterol from the admission level of 52 mg/dL to 63– 93 mg/dL. Indeed, the next cholesterol level obtained was 77 mg/dL. However, the cholesterol level continued to increase to 137 mg/dL by POD8 despite the decreasing FFP requirement. We found the cholesterol level an acceptable marker of acute functional hepatic
recovery. AFLP never resolves before delivery, therefore expeditious delivery is the penultimate therapeutic intervention. We administered a general anesthetic rather than risking a protracted time to correct the coagulopathy to provide a regional block. Another important anesthetic consideration in these patients is increased intracranial pressure (ICP). This patient had evidence of mild neurologic dysfunction with a Glasgow Coma Scale score of 15, but careful neurologic monitoring is essential to AFLP management. Documentation of the mental status
before and after a general anesthetic is crucial. Comprehensive perioperative planning after early intervention at the community hospital should include further consultation with and possible transfer to a center capable of liver transplantation (15). The indication for liver transplantation in these patients is neurologic deterioration in the presence of increased ICP. In most cases, however, with intensive support, patients recover within the first postpartum week.






Anesth Analg May 2001 92:1268-1270

2 comentarios:

  1. Como muestras en tu caso son dos patologias de la embarazada que tienen mucho en comun en cuanto a la clínica que presentan, pero se ha observado que el inicio y la agresividad del AFLP es mucho mas rapido y con una morbimortalidad bien elevada en comparación con la pre-eclampsia y el sindrome de HELLP. Paciente con embarazo de 34 semanas en un hospital de 3 nivel y que presente trastornos tan agresivos a su sistema hepatico, renal y hematologico sea un inicio de HELLP o un AFLP lo mas sano seria la terminación de embarazo y posterior a esto la compensación de los trastornos que esta presentando la madre siempre teniendo en cuenta que una paciente pre-eclamptica una vez extraido el producto se produce un retorno a la normalidad progresivo de los parametros maternos, por el contrario en la paciente con AFLP tarda mucho mas en regresar a la normalidad por lo que necesita aun un manejo mas agresivo.

    ResponderEliminar
  2. Este tipo de pacientes habitualmente será trasladada por el servicio de Obstetricia a un tercer nivel, sin embargo puede que llegue una paciente que no pueda ser trasladada y sería necesario atender en nuestras instlaciones. El manejo de soporte es parte esencial, soporte hematológico sobre todo, apoyo metabólico, renal cuando es necesario, y la terminación del embarazo procurando el bienestar del binomio madre-feto.

    ResponderEliminar

Recuerde que sus comentarios son valiosos, hágalos con respeto y con la intención de ayudarnos a mejorar los contenidos, esto puede redundar en beneficio para todos. Muchas gracias!!!